While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors find concerning. In trials of Wegovy, up to 40% of weight loss was from a decrease in lean or fat-free mass, rather than excess fat. In addition, quitting the drugs can mean adding back the pounds.

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated and prescribed. Glass points out that obesity is a complex condition, and people with obesity often have other health issues as well, related to the heart, kidney, and liver. “It’s not just about weight,” he says.

A trial was conducted comparing weight loss medications Zepbound and Wegovy ... lost almost 50% more weight than individuals using Novo Nordisk’s Wegovy. According to a study funded by Eli Lilly, the trial revealed that participants taking tirzepatide ...

Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound copycats is enforced this month, its CEO said on Wednesday after the company cut its 2025 forecasts.

A new generation of GLP-1 drugs promising fast results continues to rock the weight loss industry, which has emphasized dieting and other slow behavioral changes for decades. If WeightWatchers can weather the storm remains to be seen, but complete transformation might be the only option if the 60-year-old company plans to make it in the Wegovy era.